Stephen A. Bent

Partner/Retired

Stephen A. Bent

Partner/Retired

Stephen A. Bent, a retired partner with Foley & Lardner LLP, was a member of the Chemical, Biotechnology & Pharmaceutical Practice and the Health Care and Nanotechnology Industry Teams. He is the founder and a former co-chair of the Life Sciences Industry Team. Stephen counseled clients on intellectual property disputes and the legal issues associated with pharmaceutical and biotechnology asset valuation and management, venture capital, licensing and technology transfer, and corporate acquisitions. He was a principal in the firm’s China initiative.

柏思迪(Stephen A. Bent)是美国富理达律师事务所的合伙人,是事务所生物技术及制药执业组, 以及医疗保健和纳米技术工业团队成员之一。柏思迪先生是本所的生命科学工业团队创始人及前任领导人之一。柏先生为客户提供多方位的法律咨询,包括知识产权的纠纷解决, 与制药及生物技术相关的资产评估和管理、风险投资、许可和技术转让,以及公司收购。柏先生也是本所拓展中国市场的决策人之一, 并且参与富理达上海办公室的业务。

柏思迪先生在生物技术知识产权法领域世界闻名,在科学和法律杂志上发表过多篇文章。自从2004年以来,在实用法律公司(Practical Law Company)的《跨境生命科学手册》(Cross Border Life Sciences Handbook)知识产权类别排名中,柏先生蝉联美国五大生命科学律师之一。自从2007年以来,柏先生还连年被同行选为美国生物技术法领域最佳律师(The Best Lawyers in America®)之一。在律商联讯Martindale-Hubbell举办的同行审查评价制度中,柏先生获得该评价最优秀表现的AV® Preeminent™等级。

柏思迪先生先后毕业于厄勒姆学院(生物学理学士),康涅狄格大学(1976年,获理科硕士),乔治华盛顿大学法学院(1981年,法学博士,获成绩优异奖)。柏先生1981年至1983年曾任美国联邦巡回上诉法院巡回法官菲利浦·B·鲍德温的技术助理。他目前是《科学家》(The Scientist)杂志的编辑委员会成员。

Awards and Recognition

The Practical Law Company’s Cross Border Life Sciences Handbook has ranked Mr. Bent as one of the top five U.S. life sciences attorneys in the IP category annually since 2004. Since 2007, he also has been selected annually by his peers for inclusion in The Best Lawyers in America© for the areas of biotechnology and patent law. Mr. Bent has also been Peer Review Rated as AV® Preeminent™, the highest performance rating in Martindale-Hubbell’s peer review rating system. In 2012 – 2014, he was recognized by the Legal 500 for his work in patent prosecution and in 2013 – 2015, he was selected for inclusion in the Washington, D.C. Super Lawyers® lists for his work in intellectual property and health care.

Thought Leadership

Mr. Bent has developed an international reputation in biotechnology intellectual property law, with a number of publications to his credit in both scientific and legal journals.